Best known as a pioneer of understanding the mechanisms responsible for the generation of anti-tumor immunity, Dr. Dranoff is credited with laying the foundations for the first approved therapeutic cancer vaccine as well as the first monoclonal antibody that blocks negative immune regulation. In his current research he hopes to continue combining immunotherapies in the same patient by further studying the mechanisms of priming immune cells, immunomodulation, and the effect of the tumor microenvironment on immune cells. After several decades as professor of medicine at Dana Farber Cancer Institute of Harvard Medical School, Dr. Dranoff recently became Global Head of Exploratory Immunology at Novartis Institutes for BioMedical Research.

CTLA-4 Blockade Works by Reducing Intratumoral Tregs and Activating Teffs

Combined Local Radiotherapy and Systemic CTLA-4 Antibody Produce Sustained Remission
Anti-mesothelin CAR-T Cells Induce Antibodies to Self Epitopes and Antitumor Activity

Mechanisms Described for How anti-VEGF Aids CTLA-4 Blockade in Melanoma

2015 Immunology Program Heads Named Editors-in-Chief

ROBERT D. SCHREIBER, PHD, EDITOR-IN-CHIEF, 2015-PRESENT

PHILIP D. GREENBERG, MD, EDITOR-IN-CHIEF, 2015-PRESENT